QUARTERLY FINANCIAL INFORMATION AS OF 30 SEPTEMBER 2014

Longjumeau, November 6, 2014

In millions of euros  2013  2014  %   At constant exchange rates  %
           
 Net sales as of 30 September  126,9    117,9    -7,1%  118,6    -6,6%
  including Pharmaceutical Synthesis  81,9    74,0    -9,6%  74,6    -8,9%
  including Fine Speciality Chemicals  45,1    43,9    -2,7%  44,0    -2,4%


Consolidated net sales for the PCAS Group were down 6.6% at a constant exchange rate as of 30 September 2014 compared to the same period for the previous year.

Pharmaceutical Synthesis
Pharmaceutical Synthesis activities were down 8.9% compared to the end of September 2013, impacted by deliveries delayed to the last quarter of 2014.

Fine Specialty Chemicals
Net sales of Fine Specialty Chemicals were down 2.4% compared to the end of September 2013. Fragrances and Cosmetics activities are suffering from a gloomy economic outlook, while New Technologies, below expectations at the end of September, performed well in the third quarter of 2014 compared to the same period in the previous year and Performance Chemicals showed continued growth at the end of September 2014. 

Thanks to a busy fourth quarter of 2014 showing an increase in net sales of over 25% compared to the fourth quarter of 2013, PCAS Group sales in 2014 should be slightly higher than on those of 2013.

PCAS - Q3 Sales 2014:
http://hugin.info/143512/R/1869459/657320.pdf


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCAS via Globenewswire
HUG#1869459